

Ka Papp

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2182694/ka-papp-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

313
papers

27,757
citations

79
h-index

162
g-index

324
ext. papers

32,125
ext. citations

6.9
avg, IF

6.79
L-index

#	Paper	IF	Citations
313	The contribution of itch and skin severity improvements to the Dermatology Life Quality Index in patients with atopic dermatitis in baricitinib phase 3 trials.. <i>British Journal of Dermatology</i> , 2022 ,	4	
312	Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial.. <i>Dermatology and Therapy</i> , 2022 , 12, 495	4	6
311	Effects of Risankizumab on Nail Psoriasis in Patients with Active Psoriatic Arthritis: Results from KEEPsAKE-1.. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022 ,	4.6	1
310	Real-World Moderate-to-Severe Hidradenitis Suppurativa: Decrease in Disease Burden With Adalimumab.. <i>Journal of Cutaneous Medicine and Surgery</i> , 2022 , 12034754221088584	1.6	0
309	Use of Systemic Therapies for Treatment of Psoriasis in People Living with Controlled HIV: Inference-Based Guidance from a Multidisciplinary Expert Panel.. <i>Dermatology and Therapy</i> , 2022 , 12, 1073	4	0
308	Phase 3 Trials of Tapinarof Cream for Plaque Psoriasis. <i>New England Journal of Medicine</i> , 2021 , 385, 2219-2229	32.8	2298
307	Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial.. <i>Annals of the Rheumatic Diseases</i> , 2021 ,	2.4	10
306	Treatment satisfaction, safety, and effectiveness of adding methotrexate to adalimumab in psoriasis patients responding sub-optimally to adalimumab in a real-world setting. <i>British Journal of Dermatology</i> , 2021 ,	4	0
305	Real-world, long-term treatment patterns of commonly used biologics in Canadian patients with moderate-to-severe chronic plaque psoriasis. <i>Journal of Dermatology</i> , 2021 ,	1.6	2
304	Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial. <i>Annals of the Rheumatic Diseases</i> , 2021 ,	2.4	6
303	Consistent safety profile with up to 5 years of continuous treatment with guselkumab: Pooled analyses from the phase 3 VOYAGE 1 and VOYAGE 2 trials of patients with moderate-to-severe psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2021 ,	4.5	7
302	Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis. <i>British Journal of Dermatology</i> , 2021 ,	4	4
301	IL17A/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study. <i>Lancet, The</i> , 2021 , 397, 1564-1575	40	28
300	Psoriasis Prevalence and Severity by Expert Elicitation. <i>Dermatology and Therapy</i> , 2021 , 11, 1053-1064	4	7
299	Deterioration of Health-Related Quality of Life After Withdrawal of Risankizumab Treatment in Patients with Moderate-to-Severe Plaque Psoriasis: A Machine Learning Predictive Model. <i>Dermatology and Therapy</i> , 2021 , 11, 1291-1304	4	1
298	Baricitinib in patients with moderate-to-severe atopic dermatitis: Results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5). <i>Journal of the American Academy of Dermatology</i> , 2021 , 85, 62-70	4.5	27
297	Efficacy and safety of apremilast in patients with mild-to-moderate plaque psoriasis: Results of a phase 3, multicenter, randomized, double-blind, placebo-controlled trial. <i>Journal of the American Academy of Dermatology</i> , 2021 ,	4.5	1

296	Bimekizumab versus Adalimumab in Plaque Psoriasis. <i>New England Journal of Medicine</i> , 2021 , 385, 130-141.	4.2	28
295	Twice-weekly topical calcipotriene/betamethasone dipropionate foam as proactive management of plaque psoriasis increases time in remission and is well tolerated over 52 weeks (PSO-LONG trial). <i>Journal of the American Academy of Dermatology</i> , 2021 , 84, 1269-1277	4.5	18
294	A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial. <i>British Journal of Dermatology</i> , 2021 , 184, 1047-1058	4	24
293	Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial. <i>Lancet, The</i> , 2021 , 397, 487-498	4.0	51
292	Position statement for a pragmatic approach to immunotherapeutics in patients with inflammatory skin diseases during the coronavirus disease 2019 pandemic and beyond. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021 , 35, 797-806	4.6	5
291	Long-term safety and efficacy of a fixed-combination halobetasol propionate 0.01%/tazarotene 0.045% lotion in moderate-to-severe plaque psoriasis: phase 3 open-label study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021 , 35, 1152-1160	4.6	5
290	Efficacy and safety of apremilast in patients with moderate-to-severe plaque psoriasis of the scalp: results up to 32 weeks from a randomized, phase III study. <i>British Journal of Dermatology</i> , 2021 , 185, 840-842	4	0
289	Efficacy and safety of proactive treatment with twice-weekly topical Cal/BD foam in patients with plaque psoriasis undergoing HPA-axis testing: a PSO-LONG subgroup analysis. <i>Journal of Dermatological Treatment</i> , 2021 , 1-8	2.8	1
288	Long-Term Proactive Treatment of Plaque Psoriasis with Calcipotriene/Betamethasone Dipropionate Foam Prolongs Remission and Reduces Relapses Irrespective of Patient Baseline Characteristics. <i>Dermatology and Therapy</i> , 2021 , 11, 1657-1665	4	0
287	Real-world effectiveness of adalimumab in patients with moderate-to-severe hidradenitis suppurativa: the 1-year SOLACE study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021 , 35, 2431-2439	4.6	4
286	Safety of Janus kinase (JAK) inhibitors in the short-term treatment of atopic dermatitis. <i>International Journal of Dermatology</i> , 2021 ,	1.7	1
285	Emerging paradigm shift toward proactive topical treatment of psoriasis: A narrative review. <i>Dermatologic Therapy</i> , 2021 , 34, e15104	2.2	0
284	Population pharmacokinetic and exposure-efficacy analysis of ixekizumab in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS). <i>British Journal of Clinical Pharmacology</i> , 2021 ,	3.8	1
283	Long-term efficacy and safety of risankizumab for the treatment of moderate-to-severe plaque psoriasis: interim analysis of the LIMMitless open-label extension trial beyond 3 years of follow-up. <i>British Journal of Dermatology</i> , 2021 ,	4	7
282	Practical Management of Patients with Atopic Dermatitis on Dupilumab. <i>Dermatology and Therapy</i> , 2021 , 11, 1805-1828	4	0
281	Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studies. <i>Journal of the American Academy of Dermatology</i> , 2021 , 85, 863-872	4.5	29
280	Long-Term Safety and Efficacy of Risankizumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: Results from a Phase 2 Open-Label Extension Trial. <i>Dermatology and Therapy</i> , 2021 , 11, 487-497	4	0
279	Practical and Relevant Guidelines for the Management of Psoriasis: An Inference-Based Methodology.. <i>Dermatology and Therapy</i> , 2021 , 12, 253	4	1

278	Bimekizumab for patients with moderate to severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled, phase 2b extension study. <i>Journal of the American Academy of Dermatology</i> , 2020 , 83, 1367-1374	4.5	28
277	Management of Plaque Psoriasis With Biologic Therapies in Women of Child-Bearing Potential Consensus Paper. <i>Journal of Cutaneous Medicine and Surgery</i> , 2020 , 24, 35-145	1.6	9
276	Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials. <i>Dermatology and Therapy</i> , 2020 , 10, 431-447	4	21
275	Efficacy of Brodalumab for Moderate to Severe Plaque Psoriasis: A Canadian Network Meta-Analysis. <i>Journal of Cutaneous Medicine and Surgery</i> , 2020 , 24, 561-572	1.6	4
274	Effects of ruxolitinib cream on pruritus and quality of life in atopic dermatitis: Results from a phase 2, randomized, dose-ranging, vehicle- and active-controlled study. <i>Journal of the American Academy of Dermatology</i> , 2020 , 82, 1305-1313	4.5	39
273	Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical Trial. <i>JAMA Dermatology</i> , 2020 , 156, 649-658	5.1	62
272	Tofacitinib in psoriatic arthritis patients: skin signs and symptoms and health-related quality of life from two randomized phase 3 studies. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020 , 34, 2809-2820	4.6	5
271	Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials. <i>Rheumatology</i> , 2020 , 59, 3834-3844	3.9	23
270	Efficacy and safety of tildrakizumab for plaque psoriasis with continuous dosing, treatment interruption, dose adjustments and switching from etanercept: results from phase III studies. <i>British Journal of Dermatology</i> , 2020 , 182, 1359-1368	4	14
269	An indirect comparison of long-term efficacy of every-2-week dosing vs. recommended dosing of ixekizumab in patients who had static Physician® Global Assessment > 1 at week 12. <i>British Journal of Dermatology</i> , 2020 , 183, 52-59	4	2
268	Treatment of atopic dermatitis with ruxolitinib cream (JAK1/JAK2 inhibitor) or triamcinolone cream. <i>Journal of Allergy and Clinical Immunology</i> , 2020 , 145, 572-582	11.5	75
267	A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial. <i>British Journal of Dermatology</i> , 2020 , 182, 1348-1358	4	58
266	Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials. <i>Journal of the American Academy of Dermatology</i> , 2020 , 82, 936-945	4.5	38
265	Baseline patient-reported outcomes from UNITE: an observational, international, multicentre registry to evaluate hidradenitis suppurativa in clinical practice. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020 , 34, 1302-1308	4.6	7
264	Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of Exposure. <i>Dermatology and Therapy</i> , 2020 , 10, 133-150	4	29
263	Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial. <i>Journal of Allergy and Clinical Immunology</i> , 2020 , 145, 877-884	11.5	129
262	Trial of Roflumilast Cream for Chronic Plaque Psoriasis. <i>New England Journal of Medicine</i> , 2020 , 383, 229-239	5.9	23
261	Continuous treatment with guselkumab maintains clinical responses through 4 years in patients with moderate-to-severe psoriasis: results from VOYAGE 1. <i>Journal of Dermatological Treatment</i> , 2020 , 1-9	2.8	11

260	Abrocitinib: a potential treatment for moderate-to-severe atopic dermatitis. <i>Expert Opinion on Investigational Drugs</i> , 2020 , 29, 911-917	5.9	1
259	AURIEL-PsO: a randomized, double-blind phase III equivalence trial to demonstrate the clinical similarity of the proposed biosimilar MSB11022 to reference adalimumab in patients with moderate-to-severe chronic plaque-type psoriasis. <i>British Journal of Dermatology</i> , 2020 , 182, 316-326	4	22
258	Assessment of the effects of immunogenicity on the pharmacokinetics, efficacy and safety of tildrakizumab. <i>British Journal of Dermatology</i> , 2020 , 182, 180-189	4	14
257	Sustained efficacy of secukinumab in patients with moderate-to-severe palmoplantar psoriasis: 25-year results from GESTURE, a randomized, double-blind, placebo-controlled trial. <i>British Journal of Dermatology</i> , 2020 , 182, 889-899	4	13
256	Long-term efficacy and safety of brodalumab in psoriasis through 120 weeks and after withdrawal and retreatment: subgroup analysis of a randomized phase III trial (AMAGINE-1). <i>British Journal of Dermatology</i> , 2020 , 183, 1037-1048	4	11
255	Efficacy and safety of ixekizumab in a phase III, randomized, double-blind, placebo-controlled study in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS). <i>British Journal of Dermatology</i> , 2020 , 183, 231-241	4	40
254	Efficacy, Safety, and Patient-Reported Outcomes in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab for 5 Years in a Long-Term, Open-Label, Phase II Study. <i>American Journal of Clinical Dermatology</i> , 2019 , 20, 863-871	7.1	19
253	Vaccination Guidelines for Patients with Immune-mediated Disorders Taking Immunosuppressive Therapies: Executive Summary. <i>Journal of Rheumatology</i> , 2019 , 46, 751-754	4.1	14
252	Rationale, objectives and design of PURE, a prospective registry of patients with moderate to severe chronic plaque psoriasis in Canada and Latin America. <i>BMC Dermatology</i> , 2019 , 19, 9	2.1	2
251	Sustained long-term efficacy and safety of adalimumab in paediatric patients with severe chronic plaque psoriasis from a randomized, double-blind, phase III study. <i>British Journal of Dermatology</i> , 2019 , 181, 1177-1189	4	18
250	Efficacy of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials at weeks 12 and 28. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019 , 33, 1098-1106	4.6	14
249	Efficacy and safety of mirikizumab (LY3074828) in the treatment of moderate-to-severe plaque psoriasis: results from a randomized phase II study. <i>British Journal of Dermatology</i> , 2019 , 181, 88-95	4	42
248	Treating to Target(s) With Interleukin-17 Inhibitors. <i>Journal of Cutaneous Medicine and Surgery</i> , 2019 , 23, 3S-34S	1.6	3
247	Ixekizumab: An Effective and Safe Treatment for Moderate-to-Severe Plaque Psoriasis in Patients Previously Treated With Other IL-17 Inhibitors: Results From IXORA-P. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2019 , 4, 180-185	1.1	2
246	Tildrakizumab efficacy and impact on quality of life up to 52 weeks in patients with moderate-to-severe psoriasis: a pooled analysis of two randomized controlled trials. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019 , 33, 2305-2312	4.6	15
245	Comprehensive long-term safety of adalimumab from 18 clinical trials in adult patients with moderate-to-severe plaque psoriasis. <i>British Journal of Dermatology</i> , 2019 , 180, 76-85	4	15
244	Granulocyte-macrophage colony-stimulating factor (GM-CSF) as a therapeutic target in psoriasis: randomized, controlled investigation using namilumab, a specific human anti-GM-CSF monoclonal antibody. <i>British Journal of Dermatology</i> , 2019 , 180, 1352-1360	4	22
243	Improvement in Patient-Reported Outcomes (Dermatology Life Quality Index and the Psoriasis Symptoms and Signs Diary) with Guselkumab in Moderate-to-Severe Plaque Psoriasis: Results From the Phase III VOYAGE 1 and VOYAGE 2 Studies. <i>American Journal of Clinical Dermatology</i> , 2019 , 20, 155-164	7.1	16

242	Safety of guselkumab in patients with moderate-to-severe psoriasis treated through 100 weeks: a pooled analysis from the randomized VOYAGE 1 and VOYAGE 2 studies. <i>British Journal of Dermatology</i> , 2019 , 180, 1039-1049	4	41
241	Dupilumab: A review of its use in the treatment of atopic dermatitis. <i>Journal of the American Academy of Dermatology</i> , 2018 , 78, S28-S36	4.5	135
240	Patient-reported symptoms and signs of moderate-to-severe psoriasis treated with guselkumab or adalimumab: results from the randomized VOYAGE 1 trial. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018 , 32, 1515-1522	4.6	10
239	OBSERVE-5: Comparison of Etanercept-Treated Psoriasis Patients From Canada and the United States. <i>Journal of Cutaneous Medicine and Surgery</i> , 2018 , 22, 297-303	1.6	1
238	Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE-2 and AMAGINE-3. <i>British Journal of Dermatology</i> , 2018 , 179, 320-328	4	36
237	Randomized, controlled study of bleselumab (ASKP1240) pharmacokinetics and safety in patients with moderate-to-severe plaque psoriasis. <i>Biopharmaceutics and Drug Disposition</i> , 2018 , 39, 245-255	1.7	19
236	Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial. <i>Journal of the American Academy of Dermatology</i> , 2018 , 79, 277-286.e10	4.5	105
235	Shifting the focus - the primary role of IL-23 in psoriasis and other inflammatory disorders. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018 , 32, 1111-1119	4.6	47
234	Efficacy and safety of continuous every-2-week dosing of ixekizumab over 52 weeks in patients with moderate-to-severe plaque psoriasis in a randomized phase III trial (IXORA-P). <i>British Journal of Dermatology</i> , 2018 , 178, 1315-1323	4	36
233	Clinical Trial and Registry Data. <i>Current Problems in Dermatology</i> , 2018 , 53, 15-27		5
232	Response to Psoriasis patients' preference for an aerosol foam topical formulation by Vender R et al. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018 , 32, e401-e402	4.6	
231	Effect of psoriatic arthritis on ixekizumab clinical outcomes in moderate-to-severe psoriasis patients: A post hoc analysis. <i>Journal of the American Academy of Dermatology</i> , 2018 , 79, 593-595	4.5	3
230	Persistency of Biologic Therapies for Plaque Psoriasis in 2 Large Community Practices. <i>Journal of Cutaneous Medicine and Surgery</i> , 2018 , 22, 38-43	1.6	7
229	A Treatment Algorithm for Moderate to Severe Atopic Dermatitis in Adults. <i>Journal of Cutaneous Medicine and Surgery</i> , 2018 , 22, 78-83	1.6	9
228	Psychiatric adverse events during treatment with brodalumab: Analysis of psoriasis clinical trials. <i>Journal of the American Academy of Dermatology</i> , 2018 , 78, 81-89.e5	4.5	95
227	Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial. <i>Journal of the American Academy of Dermatology</i> , 2018 , 78, 90-99.e1	4.5	44
226	Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3). <i>British Journal of Dermatology</i> , 2018 , 178, 674-681	4	57
225	Comparison of Adalimumab and Etanercept for the Treatment of Moderate to Severe Psoriasis: An Indirect Comparison Using Individual Patient Data From Randomized Trials. <i>Value in Health</i> , 2018 , 21, 1-8	3.3	8

224	Safety of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials. <i>British Journal of Dermatology</i> , 2018 , 179, 615-622	4	39
223	Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. <i>Lancet, The</i> , 2018 , 392, 650-661	40	283
222	Diagnosis and Management of Conjunctivitis for the Dermatologist. <i>Journal of Cutaneous Medicine and Surgery</i> , 2018 , 22, 200-206	1.6	12
221	Efficacy and safety of dupilumab for the treatment of moderate-to-severe atopic dermatitis in adults: A pooled analysis of two phase 2 clinical trials. <i>Journal of the American Association of Nurse Practitioners</i> , 2018 , 30, 529-541	1	4
220	Efficacy of Tofacitinib for the Treatment of Psoriatic Arthritis: Pooled Analysis of Two Phase 3 Studies. <i>Rheumatology and Therapy</i> , 2018 , 5, 567-582	4.4	28
219	Approach to the Assessment and Management of Adult Patients With Atopic Dermatitis: A Consensus Document. Section II: Tools for Assessing the Severity of Atopic Dermatitis. <i>Journal of Cutaneous Medicine and Surgery</i> , 2018 , 22, 105-165	1.6	13
218	Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis. <i>New England Journal of Medicine</i> , 2018 , 379, 1313-1321	59.2	171
217	Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study. <i>Lancet, The</i> , 2018 , 391, 2213-2224	40	113
216	Long-Term Efficacy of Guselkumab for the Treatment of Moderate-to-Severe Psoriasis: Results from the Phase 3 VOYAGE 1 Trial Through Two Years. <i>Journal of Drugs in Dermatology</i> , 2018 , 17, 826-832	2.2	26
215	Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. <i>Journal of the American Academy of Dermatology</i> , 2017 , 76, 105-117	4.5	476
214	Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3). <i>American Journal of Clinical Dermatology</i> , 2017 , 18, 273-280	7.1	26
213	Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017 , 31, 1004-1013	4.6	40
212	Open-label study of etanercept treatment in patients with moderate-to-severe plaque psoriasis who lost a satisfactory response to adalimumab. <i>British Journal of Dermatology</i> , 2017 , 177, 411-418	4	8
211	Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for 156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2). <i>Journal of the American Academy of Dermatology</i> , 2017 , 77, 310-317.e1	4.5	110
210	Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis. <i>New England Journal of Medicine</i> , 2017 , 376, 1551-1560	59.2	306
209	Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomised, double-blind, phase 3 trial. <i>Lancet, The</i> , 2017 , 390, 40-49	40	73
208	Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , 2017 , 389, 2287-2303	40	559
207	Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. <i>Lancet, The</i> , 2017 , 390, 276-288	40	302

206	Phase I randomized study of KHK4083, an anti-OX40 monoclonal antibody, in patients with mild to moderate plaque psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017 , 31, 1324-1332	4.6	12
205	Infections from seven clinical trials of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriasis. <i>British Journal of Dermatology</i> , 2017 , 177, 1537-1551	4	31
204	Treating Psoriasis and Psoriatic Arthritis: Position Paper on Applying the Treat-to-target Concept to Canadian Daily Practice. <i>Journal of Rheumatology</i> , 2017 , 44, 519-534	4.1	14
203	Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: A randomized, double-blind, multicenter, phase III study. <i>Journal of the American Academy of Dermatology</i> , 2017 , 76, 1093-1102	4.5	74
202	Evaluating Dosage Optimality for Tofacitinib, an Oral Janus Kinase Inhibitor, in Plaque Psoriasis, and the Influence of Body Weight. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2017 , 6, 322-330	4.5	10
201	Management of Moderate to Severe Plaque Psoriasis: The Emerging Role of IL-17 Inhibition. <i>Journal of Cutaneous Medicine and Surgery</i> , 2017 , 21, 2S-40S	1.6	5
200	Management of chronic spontaneous urticaria (CSU): a treat to target approach using a patient reported outcome. <i>Allergy, Asthma and Clinical Immunology</i> , 2017 , 13, 38	3.2	4
199	Safety and Immunogenicity of Inactivated Varicella-Zoster Virus Vaccine in Adults With Autoimmune Disease: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Clinical Trial. <i>Clinical Infectious Diseases</i> , 2017 , 65, 1174-1182	11.6	22
198	European S3-Guideline on the systemic treatment of psoriasis vulgaris - Update Apremilast and Secukinumab - EDF in cooperation with EADV and IPC. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017 , 31, 1951-1963	4.6	86
197	Rapid onset of action in patients with moderate-to-severe psoriasis treated with brodalumab: A pooled analysis of data from two phase 3 randomized clinical trials (AMAGINE-2 and AMAGINE-3). <i>Journal of the American Academy of Dermatology</i> , 2017 , 77, 372-374	4.5	32
196	Tofacitinib for the treatment of moderate to severe chronic plaque psoriasis in Japanese patients: Subgroup analyses from a randomized, placebo-controlled phase 3 trial. <i>Journal of Dermatology</i> , 2017 , 44, 1228-1237	1.6	16
195	Clinical similarity of the biosimilar ABP 501 compared with adalimumab after single transition: long-term results from a randomized controlled, double-blind, 52-week, phase III trial in patients with moderate-to-severe plaque psoriasis. <i>British Journal of Dermatology</i> , 2017 , 177, 1562-1574	4	46
194	Patients with psoriasis have different preferences for topical therapy, highlighting the importance of individualized treatment approaches: randomized phase IIIb PSO-INSIGHTFUL study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017 , 31, 1876-1883	4.6	24
193	Comment on "Quantitative Evaluation of Biologic Therapy Options for Psoriasis: A Systematic Review and Network Meta-Analysis". <i>Journal of Investigative Dermatology</i> , 2017 , 137, 2642-2644	4.3	2
192	An Open Letter to Health Canada. <i>Journal of Cutaneous Medicine and Surgery</i> , 2017 , 21, 195-196	1.6	
191	Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data. <i>Journal of the American Academy of Dermatology</i> , 2017 , 76, 432-440.e175	4.5	88
190	Review of Systemic Treatment Options for Adult Atopic Dermatitis. <i>Journal of Cutaneous Medicine and Surgery</i> , 2017 , 21, 31-39	1.6	35
189	Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial. <i>Lancet, The</i> , 2016 , 387, 40-52	4.0	360

188	Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016 , 30, 1148-58	4.6	162
187	Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial. <i>British Journal of Dermatology</i> , 2016 , 175, 902-911	4	263
186	Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis. <i>New England Journal of Medicine</i> , 2016 , 375, 345-56	59.2	505
185	A Novel Aerosol Foam Formulation of Calcipotriol and Betamethasone Has No Impact on HPA Axis and Calcium Homeostasis in Patients With Extensive Psoriasis Vulgaris. <i>Journal of Cutaneous Medicine and Surgery</i> , 2016 , 20, 44-51	1.6	32
184	Ixekizumab for psoriasis--AuthorsQeplly. <i>Lancet, The</i> , 2016 , 387, 226-7	40	3
183	Adalimumab Efficacy in Patients with Psoriasis Who Received or Did Not Respond to Prior Systemic Therapy: A Pooled Post Hoc Analysis of Results from Three Double-Blind, Placebo-Controlled Clinical Trials. <i>American Journal of Clinical Dermatology</i> , 2016 , 17, 79-86	7.1	20
182	Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study. <i>Journal of the American Academy of Dermatology</i> , 2016 , 74, 841-50	4.5	108
181	Secukinumab: Review of Clinical Evidence from the Pivotal Studies ERASURE, FIXTURE, and CLEAR. <i>Journal of Clinical and Aesthetic Dermatology</i> , 2016 , 9, S7-S12	1.2	6
180	Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a Phase 2b randomized clinical trial. <i>BMC Dermatology</i> , 2016 , 16, 15	2.1	51
179	Predictors of Topical Use in Psoriasis Patients in the REFINE Study. <i>Journal of Cutaneous Medicine and Surgery</i> , 2016 , 20, 106-12	1.6	1
178	Clinical meaningfulness of complete skin clearance in psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2016 , 75, 77-82.e7	4.5	65
177	A Review of Psoriasis, Therapies, and Suicide. <i>Journal of Cutaneous Medicine and Surgery</i> , 2016 , 20, 293-303	3	28
176	A Highly Sensitive and Drug-Tolerant Anti-Drug Antibody Screening Assay for Ixekizumab using Affinity Capture Elution. <i>Journal of Investigative Dermatology</i> , 2016 , 136, 1513-1515	4.3	8
175	Ixekizumab for treatment of adults with moderate-to-severe plaque psoriasis and psoriatic arthritis. <i>Expert Review of Clinical Pharmacology</i> , 2016 , 9, 1423-1433	3.8	9
174	Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa. <i>New England Journal of Medicine</i> , 2016 , 375, 422-34	59.2	324
173	A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis. <i>British Journal of Dermatology</i> , 2016 , 174, 1266-76	4	156
172	A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. <i>British Journal of Dermatology</i> , 2016 , 175, 273-86	4	297
171	Efficacy of Tofacitinib for the Treatment of Moderate-to-Severe Chronic Plaque Psoriasis in Patient Subgroups from Two Randomised Phase 3 Trials. <i>Journal of Drugs in Dermatology</i> , 2016 , 15, 568-80	2.2	16

170	Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). <i>Journal of the American Academy of Dermatology</i> , 2015 , 73, 37-49	4.5	360
169	Five-year analysis from the ESPRIT 10-year postmarketing surveillance registry of adalimumab treatment for moderate to severe psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2015 , 73, 410-9.e6	4.5	49
168	Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. <i>Lancet, The</i> , 2015 , 386, 541-51	4.0	576
167	Management of egfr tki-induced dermatologic adverse events. <i>Current Oncology</i> , 2015 , 22, 123-32	2.8	50
166	A phase 2a randomized, double-blind, placebo-controlled, sequential dose-escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patients with moderate-to-severe psoriasis. <i>British Journal of Dermatology</i> , 2015 , 173, 767-76	4	68
165	Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis. <i>New England Journal of Medicine</i> , 2015 , 373, 1318-28	59.2	530
164	A Randomized, blinded assessor study to Evaluate the efficacy and safety of etanercept 50 mg once weekly plus as Needed topical agent vs. Etanercept 50 mg twice weekly in patients with moderate to severe plaque psoriasis (REFINE). <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015 , 29, 361-366	4.6	10
163	Selective Phosphodiesterase Inhibitors for Psoriasis: Focus on Apremilast. <i>BioDrugs</i> , 2015 , 29, 327-39	7.9	35
162	The psychosocial impact of hidradenitis suppurativa. <i>Journal of the American Academy of Dermatology</i> , 2015 , 73, S19-22	4.5	57
161	Improvements in patient-reported outcomes in patients with psoriasis receiving etanercept plus topical therapies: results from REFINE. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015 , 29, 1555-61	4.6	4
160	Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial. <i>British Journal of Dermatology</i> , 2015 , 173, 930-9	4	186
159	Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials. <i>British Journal of Dermatology</i> , 2015 , 173, 949-51	4.1	196
158	Evidence that a neutrophil-keratinocyte crosstalk is an early target of IL-17A inhibition in psoriasis. <i>Experimental Dermatology</i> , 2015 , 24, 529-35	4	123
157	Effects of tofacitinib on lymphocyte sub-populations, CMV and EBV viral load in patients with plaque psoriasis. <i>BMC Dermatology</i> , 2015 , 15, 8	2.1	26
156	European S3-Guidelines on the systemic treatment of psoriasis vulgaris--Update 2015--Short version--EDF in cooperation with EADV and IPC. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015 , 29, 2277-94	4.6	271
155	Efficacy and safety of brodalumab in subpopulations of patients with difficult-to-treat moderate-to-severe plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2015 , 72, 436-439.e1	4.5	39
154	Safety Surveillance for Ustekinumab and Other Psoriasis Treatments From the Psoriasis Longitudinal Assessment and Registry (PSOLAR). <i>Journal of Drugs in Dermatology</i> , 2015 , 14, 706-14	2.2	187
153	Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment. <i>Journal of the American Academy of Dermatology</i> , 2014 , 71, 1183-1190.e3	4.5	88

152	Effects of briakinumab treatment for moderate to severe psoriasis on health-related quality of life and work productivity and activity impairment: results from a randomized phase III study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014 , 28, 790-8	4.6	17
151	Secukinumab in plaque psoriasis--results of two phase 3 trials. <i>New England Journal of Medicine</i> , 2014 , 371, 326-38	59.2	1319
150	Disease characteristics in patients with and without psoriatic arthritis treated with etanercept. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014 , 28, 581-9	4.6	10
149	Long-term outcomes of interruption and retreatment vs. continuous therapy with adalimumab for psoriasis: subanalysis of REVEAL and the open-label extension study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013 , 27, 634-42	4.6	39
148	Improvements in patient-reported outcomes with apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of moderate to severe psoriasis: results from a phase IIb randomized, controlled study. <i>Health and Quality of Life Outcomes</i> , 2013 , 11, 82	3	40
147	A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis. <i>British Journal of Dermatology</i> , 2013 , 169, 137-45	4	156
146	Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics. <i>Journal of the American Academy of Dermatology</i> , 2013 , 69, 729-735	4.5	287
145	Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study. <i>British Journal of Dermatology</i> , 2013 , 168, 412-21	4	266
144	Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open-label extension trial of the interleukin-12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013 , 27, 1252-61	4.6	47
143	Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up. <i>British Journal of Dermatology</i> , 2013 , 168, 844-54	4	284
142	Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013 , 27, 1535-45	4.6	137
141	Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatment. <i>British Journal of Dermatology</i> , 2013 , 169, 992-9	4	69
140	Markers of inflammation and bone remodelling associated with improvement in clinical response measures in psoriatic arthritis patients treated with golimumab. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 83-8	2.4	44
139	Efficacy of the HPV-16/18 AS04-adjuvanted vaccine against low-risk HPV types (PATRICIA randomized trial): an unexpected observation. <i>Journal of Infectious Diseases</i> , 2013 , 208, 1391-6	7	66
138	Examining the risk of cardiovascular disease in patients with psoriasis: a critical review. <i>Journal of Cutaneous Medicine and Surgery</i> , 2013 , 17, 89-105	1.6	6
137	Preparing for subsequent entry biologics in dermatology and rheumatology in Canada. <i>Journal of Cutaneous Medicine and Surgery</i> , 2013 , 17, 340-6	1.6	2
136	Understanding and assessing potential serious adverse events: a practical approach to understanding the benefits and harm of psoriasis treatments. <i>Journal of Cutaneous Medicine and Surgery</i> , 2013 , 17, 189-96	1.6	
135	Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013 , 27, 876-83	4.6	79

134	Dose Response and Pharmacokinetics of Tofacitinib (CP-690,550), an Oral Janus Kinase Inhibitor, in the Treatment of Chronic Plaque Psoriasis. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2013 , 2, 44	4.5	4
133	A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis. <i>British Journal of Dermatology</i> , 2012 , 167, 649-57	4	95
132	Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study. <i>British Journal of Dermatology</i> , 2012 , 167, 668-77	4	233
131	Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial. <i>Lancet, The</i> , 2012 , 380, 738-46	4.0	205
130	Assessment of the long-term safety and effectiveness of etanercept for the treatment of psoriasis in an adult population. <i>Journal of the American Academy of Dermatology</i> , 2012 , 66, e33-45	4.5	69
129	Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open-label extension study for patients from REVEAL. <i>Journal of the American Academy of Dermatology</i> , 2012 , 66, 241-51	4.5	129
128	Single-blind, randomized controlled trial evaluating the treatment of facial seborrheic dermatitis with hydrocortisone 1% ointment compared with tacrolimus 0.1% ointment in adults. <i>Journal of the American Academy of Dermatology</i> , 2012 , 67, e11-5	4.5	25
127	Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trials. <i>Journal of the American Academy of Dermatology</i> , 2012 , 66, 742-51	4.5	105
126	Integrated safety analysis: short- and long-term safety profiles of etanercept in patients with psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2012 , 67, 245-56	4.5	56
125	Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study. <i>Arthritis and Rheumatism</i> , 2012 , 64, 3156-67		151
124	Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years. <i>British Journal of Dermatology</i> , 2012 , 166, 861-72	4	95
123	Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. <i>New England Journal of Medicine</i> , 2012 , 366, 1181-9	59.2	755
122	Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial. <i>Arthritis and Rheumatism</i> , 2012 , 64, 2504-17		151
121	Managing cardiovascular risk in patients with chronic inflammatory diseases. <i>Clinical Rheumatology</i> , 2012 , 31, 585-94	3.9	16
120	Efficacy and safety of adalimumab when added to inadequate therapy for the treatment of psoriasis: results of PRIDE, an open-label, multicentre, phase IIIb study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2012 , 26, 1007-13	4.6	13
119	Cost-effectiveness evaluation of clobetasol propionate shampoo (CPS) maintenance in patients with moderate scalp psoriasis: a Pan-European analysis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2012 , 26, 1407-14	4.6	5
118	A phase III, randomized, controlled trial of the fully human IL-12/23 mAb briakinumab in moderate-to-severe psoriasis. <i>Journal of Investigative Dermatology</i> , 2012 , 132, 304-14	4.3	128
117	Anti-IL-17 receptor antibody AMG 827 leads to rapid clinical response in subjects with moderate to severe psoriasis: results from a phase I, randomized, placebo-controlled trial. <i>Journal of Investigative Dermatology</i> , 2012 , 132, 2466-2469	4.3	107

116	Biologic therapy in psoriasis: perspectives on associated risks and patient management. <i>Journal of Cutaneous Medicine and Surgery</i> , 2012 , 16, 153-68	1.6	23
115	Evaluating practice patterns for managing moderate to severe plaque psoriasis: role of the family physician. <i>Canadian Family Physician</i> , 2012 , 58, e390-400	0.9	4
114	An update on the long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-up. <i>Journal of Drugs in Dermatology</i> , 2012 , 11, 300-12	2.2	45
113	PSOLAR: design, utility, and preliminary results of a prospective, international, disease-based registry of patients with psoriasis who are receiving, or are candidates for, conventional systemic treatments or biologic agents. <i>Journal of Drugs in Dermatology</i> , 2012 , 11, 1210-7	2.2	57
112	Effects of adalimumab versus placebo on risk of symptom worsening in psoriasis and subsequent impacts on health-related quality-of-life: analysis of pooled data from two randomized, double-blind, placebo-controlled, multicentre clinical trials. <i>Clinical Drug Investigation</i> , 2011 , 31, 51-60	3.2	7
111	The long-term safety of adalimumab treatment in moderate to severe psoriasis: a comprehensive analysis of all adalimumab exposure in all clinical trials. <i>American Journal of Clinical Dermatology</i> , 2011 , 12, 321-37	7.1	49
110	Epidemiology and quality of life of patients with psoriasis in Chile. <i>Actas Dermo-sifiliograficas</i> , 2011 , 102, 810-6	0.5	21
109	Switching to adalimumab for psoriasis patients with a suboptimal response to etanercept, methotrexate, or phototherapy: efficacy and safety results from an open-label study. <i>Journal of the American Academy of Dermatology</i> , 2011 , 64, 671-81	4.5	64
108	A nasally administered trivalent inactivated influenza vaccine is well tolerated, stimulates both mucosal and systemic immunity, and potentially protects against influenza illness. <i>Vaccine</i> , 2011 , 29, 1921-8	4.1	28
107	Long-term, continuous dosing of etanercept in patients with plaque psoriasis. <i>Expert Review of Dermatology</i> , 2011 , 6, 361-373		1
106	Adalimumab for moderate to severe chronic plaque psoriasis: efficacy and safety of retreatment and disease recurrence following withdrawal from therapy. <i>British Journal of Dermatology</i> , 2011 , 164, 434-41	4	79
105	Topical psoriasis therapy in the age of biologics: evidence-based treatment recommendations. <i>Journal of Cutaneous Medicine and Surgery</i> , 2011 , 15, 309-21	1.6	9
104	A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis. <i>New England Journal of Medicine</i> , 2011 , 365, 1586-96	59.2	158
103	Canadian guidelines for the management of plaque psoriasis: overview. <i>Journal of Cutaneous Medicine and Surgery</i> , 2011 , 15, 210-9	1.6	60
102	Calcipotriol plus betamethasone dipropionate gel compared with tacalcitol ointment and the gel vehicle alone in patients with psoriasis vulgaris: a randomized, controlled clinical trial. <i>Dermatology</i> , 2011 , 222, 148-56	4.4	43
101	Challenges in diagnosing latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. <i>Journal of Rheumatology</i> , 2011 , 38, 1234-43	4.1	36
100	Adalimumab for treatment of moderate to severe chronic plaque psoriasis of the hands and feet: efficacy and safety results from REACH, a randomized, placebo-controlled, double-blind trial. <i>Archives of Dermatology</i> , 2011 , 147, 429-36		77
99	Safety profile of intravenous and subcutaneous sipilizumab, an anti-CD2 monoclonal antibody, for the treatment of plaque psoriasis: results of two randomized, double-blind, placebo-controlled studies. <i>International Journal of Dermatology</i> , 2010 , 49, 818-28	1.7	16

98	A Canadian online survey to evaluate awareness and treatment satisfaction in individuals with moderate to severe plaque psoriasis. <i>International Journal of Dermatology</i> , 2010 , 49, 1368-75	1.7	30
97	Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial. <i>British Journal of Dermatology</i> , 2010 , 162, 137-46	4	76
96	Psoriasis care: new and emerging pharmacologic trends. <i>Journal of Cutaneous Medicine and Surgery</i> , 2010 , 14, 119-29	1.6	6
95	Epidemiology of moderate-to-severe plaque psoriasis in a Canadian surveyed population. <i>Journal of Cutaneous Medicine and Surgery</i> , 2010 , 14, 167-74	1.6	14
94	Clobetasol propionate shampoo 0.05% is efficacious and safe for long-term control of moderate scalp psoriasis. <i>Journal of Dermatological Treatment</i> , 2010 , 21, 185-92	2.8	17
93	Skin and nail responses after 1 year of infliximab therapy in patients with moderate-to-severe psoriasis: a retrospective analysis of the EXPRESS Trial. <i>Dermatology</i> , 2010 , 221, 172-8	4.4	42
92	Clinical development of onercept, a tumor necrosis factor binding protein, in psoriasis. <i>Current Medical Research and Opinion</i> , 2010 , 26, 2287-300	2.5	9
91	A randomized, double-blind, placebo-controlled, phase I study of MEDI-545, an anti-interferon-alfa monoclonal antibody, in subjects with chronic psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2010 , 62, 427-36	4.5	62
90	Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: rationale for dosing recommendations. <i>Journal of the American Academy of Dermatology</i> , 2010 , 63, 571-9	4.5	92
89	Comparison of two different dose combinations of calcipotriol/hydrocortisone ointment used once daily for the treatment of psoriasis vulgaris on the face and body. <i>European Journal of Dermatology</i> , 2010 , 20, 585-9	0.8	10
88	A Canadian self-administered online survey to evaluate the impact of moderate-to-severe psoriasis among patients. <i>Journal of Cutaneous Medicine and Surgery</i> , 2009 , 13, 294-302	1.6	19
87	The AWARE study: methodology and baseline characteristics. <i>Journal of Cutaneous Medicine and Surgery</i> , 2009 , 13 Suppl 3, S113-21	1.6	5
86	Monitoring patients treated with efalizumab or alefacept. <i>Current Problems in Dermatology</i> , 2009 , 38, 95-106		2
85	Patterns of combination therapy with alefacept for the treatment of psoriasis in Canada in the AWARE study. <i>Journal of Cutaneous Medicine and Surgery</i> , 2009 , 13 Suppl 3, S131-8	1.6	4
84	Adalimumab in the treatment of psoriasis: pooled efficacy and safety results from three pivotal studies. <i>Journal of Cutaneous Medicine and Surgery</i> , 2009 , 13 Suppl 2, S58-66	1.6	11
83	Update on alefacept safety. <i>Journal of Cutaneous Medicine and Surgery</i> , 2009 , 13 Suppl 3, S139-47	1.6	6
82	Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. <i>Arthritis and Rheumatism</i> , 2009 , 60, 976-86		467
81	Humanized anti-CD2 monoclonal antibody treatment of plaque psoriasis: efficacy and pharmacodynamic results of two randomized, double-blind, placebo-controlled studies of intravenous and subcutaneous siplizumab. <i>Archives of Dermatological Research</i> , 2009 , 301, 429-42	3.3	13

80	Psoriasis: consensus on topical therapies. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2008 , 22, 859-70	4.6	27
79	A study examining inter-rater and intrarater reliability of a novel instrument for assessment of psoriasis: the Copenhagen Psoriasis Severity Index. <i>British Journal of Dermatology</i> , 2008 , 159, 407-12	4	30
78	Long-term efficacy of up to 15 months of efalizumab therapy in patients with moderate-to-severe chronic plaque psoriasis. <i>Dermatologic Therapy</i> , 2008 , 21 Suppl 3, S6-14	2.2	9
77	Safety of efalizumab therapy in patients with moderate to severe psoriasis: an open-label extension of a phase IIIb trial. <i>Drug Safety</i> , 2008 , 31, 715-26	5.1	6
76	Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. <i>Journal of the American Academy of Dermatology</i> , 2008 , 58, 106-15	4.5	685
75	Monitoring biologics for the treatment of psoriasis. <i>Clinics in Dermatology</i> , 2008 , 26, 515-21	3	4
74	Efficacy of ISA247 in plaque psoriasis: a randomised, multicentre, double-blind, placebo-controlled phase III study. <i>Lancet, The</i> , 2008 , 371, 1337-42	40	67
73	Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). <i>Lancet, The</i> , 2008 , 371, 1665-74	40	1296
72	Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). <i>Lancet, The</i> , 2008 , 371, 1675-84	40	1150
71	Voclosporin (ISA247) for plaque psoriasis [Authors' reply]. <i>Lancet, The</i> , 2008 , 372, 889	40	
70	Analytical approaches to reporting long-term clinical trial data. <i>Current Medical Research and Opinion</i> , 2008 , 24, 2001-8	2.5	28
69	Targeting the interleukin-12/23 cytokine family in the treatment of psoriatic disease. <i>Journal of Cutaneous Medicine and Surgery</i> , 2008 , 12 Suppl 1, S1-10	1.6	13
68	Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis. <i>British Journal of Dermatology</i> , 2008 , 158, 549-57	4	115
67	Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). <i>British Journal of Dermatology</i> , 2008 , 158, 558-66	4	514
66	Efficacy and Safety of Adalimumab Treatment in Patients with Moderate to Severe Psoriasis: A Double-Blind, Randomized Clinical Trial. <i>Psoriasis Forum</i> , 2007 , 13a, 4-11		16
65	Eruptive papules during efalizumab (anti-CD11a) therapy of psoriasis vulgaris: a case series. <i>BMC Dermatology</i> , 2007 , 7, 2	2.1	14
64	Effects of etanercept therapy on fatigue and symptoms of depression in subjects treated for moderate to severe plaque psoriasis for up to 96 weeks. <i>British Journal of Dermatology</i> , 2007 , 157, 1275-4		90
63	Scalp psoriasis: a review of current topical treatment options. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2007 , 21, 1151-60	4.6	54

62	Mechanism of Action, Pharmacokinetics, and Drug Interactions of Etanercept in Dermatology. <i>Journal of Cutaneous Medicine and Surgery</i> , 2007 , 11, S3-S13	1.6	1
61	Etanercept: A Novel Tumor Necrosis Factor Antagonist for the Treatment of Psoriatic Disease. <i>Journal of Cutaneous Medicine and Surgery</i> , 2007 , 11, S1-S2	1.6	
60	Long-Term Safety of Etanercept. <i>Journal of Cutaneous Medicine and Surgery</i> , 2007 , 11, S23-S36	1.6	1
59	Efalizumab for the treatment of psoriatic arthritis. <i>Journal of Cutaneous Medicine and Surgery</i> , 2007 , 11, 57-66	1.6	58
58	A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2007 , 56, 31.e1-15	4.5	370
57	The safety of etanercept for the treatment of plaque psoriasis. <i>Therapeutics and Clinical Risk Management</i> , 2007 , 3, 245-58	2.9	14
56	Safety and tolerability of 1% pimecrolimus cream among infants: experience with 1133 patients treated for up to 2 years. <i>Pediatrics</i> , 2006 , 117, e118-28	7.4	90
55	Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. <i>Lancet, The</i> , 2006 , 367, 29-35	4.0	832
54	Long-term management of plaque psoriasis with continuous efalizumab therapy. <i>Journal of the American Academy of Dermatology</i> , 2006 , 54, S182-8	4.5	28
53	Relapse, rebound, and psoriasis adverse events: an advisory group report. <i>Journal of the American Academy of Dermatology</i> , 2006 , 54, S171-81	4.5	104
52	Efalizumab retreatment in patients with moderate to severe chronic plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2006 , 54, S164-70	4.5	30
51	Patients with psoriasis respond to continuous open-label etanercept treatment after initial incomplete response in a randomized, placebo-controlled trial. <i>Journal of the American Academy of Dermatology</i> , 2006 , 54, S112-9	4.5	38
50	A randomized, multicenter, double-blind, placebo-controlled phase 2 trial of ISA247 in patients with chronic plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2006 , 54, 472-8	4.5	47
49	Practical guidelines for the long-term treatment of psoriasis with efalizumab. <i>Journal of the American Academy of Dermatology</i> , 2006 , 54, S153	4.5	3
48	Evaluation of efalizumab using safe psoriasis control. <i>BMC Dermatology</i> , 2006 , 6, 8	2.1	7
47	Approaches to discontinuing efalizumab: an open-label study of therapies for managing inflammatory recurrence. <i>BMC Dermatology</i> , 2006 , 6, 9	2.1	9
46	Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial. <i>British Journal of Dermatology</i> , 2006 , 154, 1161-8	4	92
45	Clinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial. <i>British Journal of Dermatology</i> , 2006 , 155, 170-81	4	107

44	Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: a phase IIIb, randomized, controlled trial. <i>International Journal of Dermatology</i> , 2006 , 45, 605-14	1.7	61
43	The long-term efficacy and safety of new biological therapies for psoriasis. <i>Archives of Dermatological Research</i> , 2006 , 298, 7-15	3.3	74
42	A favourable benefit/risk ratio with efalizumab: a review of the clinical evidence. <i>Journal of Cutaneous Medicine and Surgery</i> , 2006 , 9 Suppl 1, 10-7	1.6	72
41	Recommendations for incorporating biologicals into management of moderate to severe plaque psoriasis: individualized patient approaches. <i>Journal of Cutaneous Medicine and Surgery</i> , 2006 , 9 Suppl 1, 18-25	1.6	7
40	Strategies for optimizing treatment with efalizumab in moderate to severe psoriasis. <i>Journal of Cutaneous Medicine and Surgery</i> , 2006 , 9 Suppl 1, 26-32	1.6	6
39	Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. <i>Lancet, The</i> , 2005 , 366, 1367-74	4.0	850
38	Long-term treatment of atopic dermatitis with pimecrolimus cream 1% in infants does not interfere with the development of protective antibodies after vaccination. <i>Journal of the American Academy of Dermatology</i> , 2005 , 52, 247-53	4.5	64
37	Long-term control of atopic dermatitis with pimecrolimus cream 1% in infants and young children: a two-year study. <i>Journal of the American Academy of Dermatology</i> , 2005 , 52, 240-6	4.5	85
36	Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial. <i>Journal of the American Academy of Dermatology</i> , 2005 , 52, 425-33	4.5	191
35	An integrated analysis of thirteen trials summarizing the long-term safety of alefacept in psoriasis patients who have received up to nine courses of therapy. <i>Clinical Therapeutics</i> , 2005 , 27, 1912-21	3.5	60
34	Potential future therapies for psoriasis. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2005 , 24, 58-63	1.4	6
33	Safety of Efalizumab in Patients with Moderate to Severe Chronic Plaque Psoriasis: Review of Clinical Data. Part II. <i>Journal of Cutaneous Medicine and Surgery</i> , 2005 , 9, 313-323	1.6	4
32	Efficacy and tolerability of three different doses of oral pimecrolimus in the treatment of moderate to severe atopic dermatitis: a randomized controlled trial. <i>British Journal of Dermatology</i> , 2005 , 152, 1296-303	4	38
31	A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. <i>British Journal of Dermatology</i> , 2005 , 152, 1304-12	4	586
30	Clinical efficacy of efalizumab in patients with chronic plaque psoriasis: results from three randomized placebo-controlled Phase III trials: part I. <i>Journal of Cutaneous Medicine and Surgery</i> , 2005 , 9, 303-12	1.6	23
29	Safety of efalizumab in patients with moderate to severe chronic plaque psoriasis: review of clinical data. part II. <i>Journal of Cutaneous Medicine and Surgery</i> , 2005 , 9, 313-23	1.6	21
28	Safe psoriasis control: a new outcome measure for the composite assessment of the efficacy and safety of psoriasis treatment. <i>Journal of Cutaneous Medicine and Surgery</i> , 2005 , 9, 276-83	1.6	8
27	Clinical Efficacy of Efalizumab in Patients with Chronic Plaque Psoriasis: Results from Three Randomized Placebo-Controlled Phase III Trials: Part I. <i>Journal of Cutaneous Medicine and Surgery</i> , 2005 , 9, 303-312	1.6	22

26	Increase in TNF-alpha and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a). <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005 , 102, 19057-62	11.5	382
25	Etanercept in psoriasis. <i>Expert Opinion on Pharmacotherapy</i> , 2004 , 5, 2139-46	4	12
24	Validation of the Eczema Area and Severity Index for atopic dermatitis in a cohort of 1550 patients from the pimecrolimus cream 1% randomized controlled clinical trials programme. <i>British Journal of Dermatology</i> , 2004 , 150, 96-102	4	113
23	Biological therapies in the systemic management of psoriasis: International Consensus Conference. <i>British Journal of Dermatology</i> , 2004 , 151 Suppl 69, 3-17	4	139
22	Effect of pimecrolimus cream 1% on the long-term course of pediatric atopic dermatitis. <i>International Journal of Dermatology</i> , 2004 , 43, 978-83	1.7	29
21	Integrating biologic agents into management of moderate-to-severe psoriasis: a consensus of the Canadian Psoriasis Expert Panel. February 27, 2004. <i>Journal of Cutaneous Medicine and Surgery</i> , 2004 , 8, 321-37	1.6	23
20	Pimecrolimus cream 1% provides effective long-term control of atopic dermatitis in infants. <i>Journal of the American Academy of Dermatology</i> , 2004 , 50, P65	4.5	4
19	Interpretation of positive patient response to efalizumab for the treatment of moderate to severe plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2004 , 50, P157	4.5	3
18	Efficacy and safety of etanercept in patients with psoriasis: results of a global phase iii study. <i>Journal of the American Academy of Dermatology</i> , 2004 , 50, P159	4.5	12
17	Integrating Biologic Agents into Management of Moderate-to-Severe Psoriasis: A Consensus of the Canadian Psoriasis Expert Panel. <i>Journal of Cutaneous Medicine and Surgery</i> , 2004 , 8, 321-337	1.6	38
16	Efalizumab: Advancing psoriasis management with a novel, targeted T-cell modulator. <i>Drugs of Today</i> , 2004 , 40, 889-99		5
15	Impact of efalizumab on psoriasis-specific patient-reported outcomes. Results from three randomized, placebo-controlled clinical trials of moderate to severe plaque psoriasis. <i>Journal of Drugs in Dermatology</i> , 2004 , 3, 27-38	2.2	49
14	Early onset of action and efficacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2003 , 48, 48-54	4.5	134
13	Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. <i>JAMA - Journal of the American Medical Association</i> , 2003 , 290, 3073-80	27.4	300
12	Randomized placebo-controlled trial of metronidazole 1% cream with sunscreen SPF 15 in treatment of rosacea. <i>Journal of Cutaneous Medicine and Surgery</i> , 2002 , 6, 529-34	1.6	16
11	Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. <i>Pediatrics</i> , 2002 , 110, e2	7.4	244
10	Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug. <i>Journal of Allergy and Clinical Immunology</i> , 2002 , 110, 277-84	11.5	206
9	A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2002 , 47, 821-33	4.5	300

8	Intermittent short courses of cyclosporine microemulsion for the long-term management of psoriasis: a 2-year cohort study. <i>Journal of the American Academy of Dermatology</i> , 2001 , 44, 643-51	4.5	117
7	The treatment of moderate to severe psoriasis with a new anti-CD11a monoclonal antibody. <i>Journal of the American Academy of Dermatology</i> , 2001 , 45, 665-74	4.5	148
6	Recombinant human platelet-derived growth factor-BB (becaplermin) for healing chronic lower extremity diabetic ulcers: an open-label clinical evaluation of efficacy. <i>Wound Repair and Regeneration</i> , 2000 , 8, 162-8	3.6	123
5	Calcipotriol cream combined with twice weekly broad-band UVB phototherapy: a safe, effective and UVB-sparing antipsoriatic combination treatment. The Canadian Calcipotriol and UVB Study Group. <i>Dermatology</i> , 2000 , 200, 17-24	4.4	61
4	The incidence of cancer associated with the treatment of rheumatoid arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 1999 , 29, 148-58	5.3	61
3	Neoral [®] in the Treatment of Psoriasis: Consensus Treatment Guidelines. <i>Journal of Cutaneous Medicine and Surgery</i> , 1997 , 1, 209-215	1.6	5
2	Systemic gold therapy. <i>Clinics in Dermatology</i> , 1991 , 9, 535-51	3	14
1	Leprotic involvement of peripheral nerves in the absence of skin lesions. Case report and literature review. <i>Journal of the American Academy of Dermatology</i> , 1990 , 23, 1023-6	4.5	24